Capricor Therapeutics (CAPR) Expected to Announce Quarterly Earnings on Wednesday

Key Points

• Capricor is set to report Q4 and full-year 2025 results before the market opens on March 18, 2026, with analysts forecasting a ($0.51) loss per share and $0.525 million in revenue, and the company will give a corporate update on March 12 that could add near-term volatility.
• FDA resumed review of the Deramiocel Biologics License Application (BLA) and lifted the prior Complete Response Letter; the resubmission is classified as Class 2 with a PDUFA target action date of August 22, 2026, representing a key regulatory catalyst.
• Shares have rallied (opened at $33.40, up ~9%) and the company has a $1.85 billion market cap; Wall Street sentiment is largely positive with a consensus rating of "Moderate Buy" and a consensus price target of $40.82, while several brokers have $50–$60 targets.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) is projected to post its Q4 2025 results before the market opens on Wednesday, March 18th. Analysts expect Capricor Therapeutics to post earnings of ($0.51) per share and revenue of $0.5250 million for the quarter. Interested persons are encouraged to explore the company's upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, March 12, 2026 at 4:30 PM ET.

Capricor Therapeutics Stock Up 9.0%

Shares of CAPR opened at $33.40 on Wednesday. The business has a fifty day moving average of $25.47 and a 200 day moving average of $16.11. The company has a market cap of $1.85 billion, a PE ratio of -18.56 and a beta of 0.37. Capricor Therapeutics has a 52-week low of $4.30 and a 52-week high of $40.37.

Capricor Therapeutics News Roundup

Here are the key news stories impacting Capricor Therapeutics this week:

• Positive Sentiment: FDA resumed review of the Biologics License Application for Deramiocel and lifted the prior Complete Response Letter; the resubmission is classified as a Class 2 with a PDUFA target action date of August 22, 2026 — a clear regulatory catalyst toward potential approval. Article Title
• Positive Sentiment: HC Wainwright reiterated a Buy rating and set a $60 price target (implying substantial upside from current levels), which can support investor confidence and buying interest. Article Title
• Neutral Sentiment: Capricor will report Q4 and full-year 2025 results and provide a corporate update on March 12 — this is a near-term event that could add volatility depending on financials and program updates. Article Title
• Neutral Sentiment: News that the FDA CBER head (Dr. Vinay Prasad) is leaving in April introduces some regulatory leadership change risk/uncertainty for biotech review dynamics, but the direct impact on CAPR’s review timeline is unclear. Article Title
• Neutral Sentiment: Reported large short-interest “increase” items show zero shares and NaN changes — this appears to be a data anomaly and is unlikely to be a meaningful driver unless later confirmed by accurate short-interest filings.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on CAPR. Maxim Group increased their target price on shares of Capricor Therapeutics from $25.00 to $50.00 and gave the company a "buy" rating in a research note on Thursday, December 4th. UBS Group set a $50.00 target price on Capricor Therapeutics in a research report on Monday, December 15th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Capricor Therapeutics in a research note on Wednesday, January 14th. iA Financial set a $48.00 price target on shares of Capricor Therapeutics in a report on Wednesday, December 3rd. Finally, Alliance Global Partners restated a "buy" rating on shares of Capricor Therapeutics in a research note on Wednesday, December 3rd. Nine research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $40.82.

Institutional Trading of Capricor Therapeutics

Several institutional investors have recently made changes to their positions in the company. Entropy Technologies LP acquired a new stake in Capricor Therapeutics in the fourth quarter valued at approximately $409,000. New York State Common Retirement Fund lifted its position in Capricor Therapeutics by 124.1% in the fourth quarter. New York State Common Retirement Fund now owns 13,000 shares of the biotechnology company's stock valued at $375,000 after acquiring an additional 7,200 shares during the last quarter. BNP Paribas Financial Markets grew its stake in Capricor Therapeutics by 2,342.8% during the 2nd quarter. BNP Paribas Financial Markets now owns 36,398 shares of the biotechnology company's stock worth $361,000 after buying an additional 34,908 shares during the last quarter. Virtus Investment Advisers LLC grew its position in shares of Capricor Therapeutics by 25.2% during the fourth quarter. Virtus Investment Advisers LLC now owns 10,224 shares of the biotechnology company's stock worth $295,000 after acquiring an additional 2,061 shares during the last quarter. Finally, Brooklyn Investment Group purchased a new position in Capricor Therapeutics during the 3rd quarter worth $274,000. Hedge funds and other institutional investors own 21.68% of the company's stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company's leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.